SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the U.S. launch of its next-generation Zio® monitor and enhanced Zio® long-term continuous ...
Findings in a younger, commercially insured population build on Medicare-based CAMELOT results, expanding the generalizability of Zio LTCM's clinical impact across patient groups. Latest data showed ...
Zio ECG monitoring system is the only fourteen-day cardiac monitoring service in its category to receive Japanese regulatory approval as an improved device without a clinical trial Zio ECG monitoring ...
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent ...
Heart disease, particularly conditions like atrial fibrillation (AFib), is a leading cause of death worldwide, and traditional cardiac monitoring methods often present challenges in patient comfort ...
Real-world data across more than 1 million patients published in Heart Rhythm show that 24–48-hour monitoring can miss actionable arrhythmias and highlights the value of iRhythm’s Zio ® long-term ...
SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the commercial launch in Japan of its Zio ® long-term continuous ECG monitoring (LTCM) system, ...
iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S. The new Zio monitor is a prescription-only ECG monitor, which is an integral part of the Zio LTCM service. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback